A phase IB, open-label, parallel design study of PTK787/ZK 222584 in combination with irinotecan in patients (Pts) with metastatic colorectal cancer (CRC) to investigate the interaction between the agents.

Teipar, S; Humblet, Yves; Lin, E; Bono, P; Jalava, T; Kay, A; Masson, E; Laurent, D; Joensuu, H; Van Cutsem, E.

A phase IB, open-label, parallel design study of PTK787/ZK 222584 in combination with irinotecan in patients (Pts) with metastatic colorectal cancer (CRC) to investigate the interaction between the agents.

Teipar, S

;

Humblet, Yves

;

Lin, E

;

Bono, P

;

Van Cutsem, E.

;et.al.

(2005) 41st Annual Meeting of the American-Society-of-Clinical-Oncology — Location: Orlando (Fl) (13.May.2005)

Files

No attached file found for this publication.

Details

Authors

Teipar, S
Author
Humblet, YvesUCLouvain
Author
Lin, E
Author
Bono, P
Author
Van Cutsem, E.
Author

Affiliations

Citations

APA
Chicago
FWB

Teipar, S., Humblet, Y., Lin, E., Bono, P., Jalava, T., Kay, A., Masson, E., Laurent, D., Joensuu, H., & Van Cutsem, E. (2005). A phase IB, open-label, parallel design study of PTK787/ZK 222584 in combination with irinotecan in patients (Pts) with metastatic colorectal cancer (CRC) to investigate the interaction between the agents. Journal of Clinical Oncology, 23(16), 269S-269S. https://hdl.handle.net/2078.5/140482 (Original work published 2005)